European Journal of Clinical Pharmacology

, Volume 24, Issue 6, pp 773–776

A phenylbutazone dose-finding study in rheumatoid arthritis

  • H. A. Bird
  • P. A. Leatham
  • J. R. Lowe
  • W. W. Downie
  • P. D. Fowler
  • V. Wright
Originals
  • 19 Downloads

Summary

Different doses of phenylbutazone have been compared in a double blind study on 32 patients with rheumatoid arthritis in order to determine the minimum effective dose. Of 8 different dose levels studied (90 mg, 150 mg, 180 mg, 240 mg, 270 mg, 300 mg, 360 mg and 450 mg/day) the most efficacious was found to be 300 mg/day. Doses below this did not produce full benefit; no further improvement occurs with higher doses. Although 7/32 patients developed adverse reactions there was no relationship between these and the plasma levels of either phenylbutazone or oxyphenbutazone. An attempt was made to distinguish ‘responders’ from ‘non-responders’. We found no relationship between response and plasma levels of phenylbutazone or oxyphenbutazone.

Key words

phenylbutazone rheumatoid arthritis dose oxyphenbutazone side effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • H. A. Bird
    • 1
    • 2
  • P. A. Leatham
    • 1
    • 2
  • J. R. Lowe
    • 1
    • 2
  • W. W. Downie
    • 1
    • 2
  • P. D. Fowler
    • 3
  • V. Wright
    • 1
    • 2
  1. 1.Clinical Pharmacology Unit, Royal Bath HospitalHarrogateUnited Kingdom
  2. 2.Rheumatism Research Unit, University Department of Medicine, General Infirmary at LeedsUnited Kingdom
  3. 3.Staffordshire Rheumatology CentreBurslem, Stoke-on-TrentUnited Kingdom

Personalised recommendations